Even more importantly, cardiac actin mutations that appear in the myosin or tropomyosin-binding regions cause either hypertrophic (HCM) or dilated (DCM) cardiomyopathies (11), increasing the motivation to discover small molecules that target actin for therapeutic treatment of actin-related diseases (12, 13). This evidence concerns the gene MYH14 and cardiomyopathy.